Product nameAnti-JAK2 antibody
See all JAK2 primary antibodies
DescriptionRabbit polyclonal to JAK2
Tested applicationsSuitable for: IP, WB, IHC-Pmore details
Species reactivityReacts with: Human
Predicted to work with: Orangutan
Synthetic peptide within Human JAK2 aa 1082-1132. The exact sequence is proprietary. (NP_004963.1).
Database link: O60674
- WB: Jurkat and HeLa whole cell lysates. IP: Jurkat whole cell lysate. IHC-P: Human prostate carcinoma tissue.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.
Storage bufferPreservative: 0.09% Sodium azide
Constituent: Tris citrate/phosphate
pH 7 to 8
Concentration information loading...
PurityImmunogen affinity purified
Purification notesab245303 was affinity purified using an epitope specific to JAK2 immobilized on solid support.
Our Abpromise guarantee covers the use of ab245303 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|IP||Use at 5-15 µg/mg of lysate.|
|WB||1/2000 - 1/10000. Predicted molecular weight: 131 kDa.|
|IHC-P||1/500 - 1/2000. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.|
FunctionNon-receptor tyrosine kinase involved in various processes such as cell cycle progression, apoptosis, mitotic recombination, genetic instability and histone modifications. In the cytoplasm, plays a pivotal role in signal transduction via its association with cytokine receptors, which constitutes an initiating step in signaling for many members of the cytokine receptor superfamily including the receptors for growth hormone (GHR), prolactin (PRLR), leptin (LEPR), erythropoietin (EPOR), granulocyte-macrophage colony-stimulating factor (CSF2), thrombopoietin (THPO) and multiple interleukins. Following stimulation with erythropoietin (EPO) during erythropoiesis, it is autophosphorylated and activated, leading to its association with erythropoietin receptor (EPOR) and tyrosine phosphorylation of residues in the EPOR cytoplasmic domain. Also involved in promoting the localization of EPOR to the plasma membrane. Also acts downstream of some G-protein coupled receptors. Plays a role in the control of body weight (By similarity). Mediates angiotensin-2-induced ARHGEF1 phosphorylation. In the nucleus, plays a key role in chromatin by specifically mediating phosphorylation of 'Tyr-41' of histone H3 (H3Y41ph), a specific tag that promotes exclusion of CBX5 (HP1 alpha) from chromatin.
Tissue specificityExpressed in blood, bone marrow and lymph node.
Involvement in diseaseNote=Chromosomal aberrations involving JAK2 are found in both chronic and acute forms of eosinophilic, lymphoblastic and myeloid leukemia. Translocation t(8;9)(p22;p24) with PCM1 links the protein kinase domain of JAK2 to the major portion of PCM1. Translocation t(9;12)(p24;p13) with ETV6.
Defects in JAK2 are a cause of susceptibility to Budd-Chiari syndrome (BCS) [MIM:600880]. It is a syndrome caused by obstruction of hepatic venous outflow involving either the hepatic veins or the terminal segment of the inferior vena cava. Obstructions are generally caused by thrombosis and lead to hepatic congestion and ischemic necrosis. Clinical manifestations observed in the majority of patients include hepatomegaly, right upper quadrant pain and abdominal ascites. Budd-Chiari syndrome is associated with a combination of disease states including primary myeloproliferative syndromes and thrombophilia due to factor V Leiden, protein C deficiency and antithrombin III deficiency. Budd-Chiari syndrome is a rare but typical complication in patients with polycythemia vera.
Defects in JAK2 are a cause of polycythemia vera (PV) [MIM:263300]. A myeloproliferative disorder characterized by abnormal proliferation of all hematopoietic bone marrow elements, erythroid hyperplasia, an absolute increase in total blood volume, but also by myeloid leukocytosis, thrombocytosis and splenomegaly.
Defects in JAK2 gene may be a cause of essential thrombocythemia (ET) [MIM:187950]. ET is characterized by elevated platelet levels due to sustained proliferation of megakaryocytes, and frequently lead to thrombotic and haemorrhagic complications.
Defects in JAK2 are a cause of myelofibrosis (MYELOF) [MIM:254450]. Myelofibrosis is a disorder characterized by replacement of the bone marrow by fibrous tissue, occurring in association with a myeloproliferative disorder. Clinical manifestations may include anemia, pallor, splenomegaly, hypermetabolic state, petechiae, ecchymosis, bleeding, lymphadenopathy, hepatomegaly, portal hypertension.
Defects in JAK2 are a cause of acute myelogenous leukemia (AML) [MIM:601626]. AML is a malignant disease in which hematopoietic precursors are arrested in an early stage of development.
Sequence similaritiesBelongs to the protein kinase superfamily. Tyr protein kinase family. JAK subfamily.
Contains 1 FERM domain.
Contains 1 protein kinase domain.
Contains 1 SH2 domain.
DomainPossesses 2 protein kinase domains. The second one probably contains the catalytic domain, while the presence of slight differences suggest a different role for protein kinase 1.
modificationsAutophosphorylated, leading to regulate its activity. Leptin promotes phosphorylation on tyrosine residues, including phosphorylation on Tyr-813. Autophosphorylation on Tyr-119 in response to EPO down-regulates its kinase activity. Autophosphorylation on Tyr-868, Tyr-966 and Tyr-972 in response to growth hormone (GH) are required for maximal kinase activity.
Cellular localizationEndomembrane system. Nucleus.
- Information by UniProt
- JAK 2 antibody
- JAK-2 antibody
- JAK2 antibody
All lanes : Anti-JAK2 antibody (ab245303) at 0.1 µg/ml
Lane 1 : Jurkat (humanT cell leukemia cell line from peripheral blood) whole cell lysate at 50 µg
Lane 2 : Jurkat whole cell lysate at 15 µg
Lane 3 : Jurkat whole cell lysate at 5 µg
Lane 4 : HeLa (human epithelial cell line from cervix adenocarcinoma) whole cell lysate at 50 µg
Developed using the ECL technique.
Predicted band size: 131 kDa
Exposure time: 30 seconds
JAK2 was immunoprecipitated from Jurkat (humanT cell leukemia cell line from peripheral blood) whole cell lysate (1 mg for IP, 20% of IP loaded) with ab245303 at 10 µg/mg lysate. Western blot was performed from the immunoprecipitate using ab245303 at 1 µg/ml.
Lane 1: ab245303 IP in Jurkat whole cell lysate.
Lane 2: Control IgG IP in Jurkat whole cell lysate.
Detection: Chemiluminescence with exposure time of 10 seconds.
Formalin-fixed, paraffin-embedded human prostate carcinoma tissue stained for JAK2 using ab245303 at 1/1000 dilution in immunohistochemical analysis. Detection: DAB staining.
ab245303 has not yet been referenced specifically in any publications.